A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 2

Conditions: Infections, Rotavirus

Treatments: Biological: Tritanrix-HB+Hib; Biological: Placebo; Biological: Rotarix; Biological: Polio Sabin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00263666

2015-001484-39 (EudraCT Number)

444563/022

Details and patient eligibility

About

The aim of this study is to evaluate the reactogenicity, safety and immunogenicity of GSK Biologicals' human rotavirus (HRV) vaccine given concomitantly with routine vaccines including OPV in HIV positive infants. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Full description

HIV infected infants as determined prior to study entry (screening) and asymptomatic or mildly symptomatic (WHO stages I and II) of disease will be enrolled. The study will have two groups: Group HRV and Group Placebo. Three-dose immunisation will be administered at approximately 6, 10, and 14 weeks of age. Routine EPI (Expanded Program on Immunisation) vaccinations will be administered concomitantly with the study vaccines. At the time of first dose, subjects will be aged 6 to 10 weeks. This study will evaluate safety, reactogenicity and immunogenicity of the HRV vaccine relative to the placebo.

Enrollment: 100 patients

Sex: All

Ages: 6 to 10 weeks old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
• A male or female between, and including 6 and 10 weeks of age at the time of the first vaccination.
• Written informed consent obtained from the parents or guardians of the subject
• Documented HIV status of the subject as confirmed by PCR.
• HIV asymptomatic and HIV mildly symptomatic; Stages I and II disease according to WHO's most recent classification for HIV stages in infants and children.
• Born after a gestation period of 36 to 42 weeks.

Exclusion criteria

• Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
• Previous routine vaccination except OPV, BCG and HBV vaccination at birth
• Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the GI tract or other serious medical condition as determined by the investigator.
• History of allergic disease or reaction likely to be exacerbated by any component of the vaccine.
• Acute disease at time of enrolment.
• Gastroenteritis within 7 days preceding the study vaccine administration.
• Previous confirmed occurrence of RV gastroenteritis.
• Other conditions which in the opinion of the investigator may potentially interfere with interpretation of study outcomes.
• HIV moderately and severely symptomatic: stages III and IV according to WHO's recent classification.
• Administration of immunoglobulins and/or blood products since birth or planned administration during the study period.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

100 participants in 2 patient groups, including a placebo group

Rotarix Group

Experimental group

Description:

Subjects received 3 doses of Rotarix vaccine co-administered with routine Tritanrix HepB Hib and Polio Sabin vaccines.

Treatment:

Biological: Polio Sabin

Biological: Rotarix

Biological: Tritanrix-HB+Hib

Placebo Group

Placebo Comparator group

Description:

Subjects received 3 doses of placebo co-administered with routine Tritanrix HepB Hib and Polio Sabin vaccines.

Treatment:

Biological: Polio Sabin

Biological: Placebo

Biological: Tritanrix-HB+Hib